Northwest Biotherapeutics (NWBO) Stock Soars 135% in a Year: But Why?

For those investors who are more interested in investing with a long term window in mind, it might be a good idea to look at stocks which have recorded gains over a reasonable period of time.

One of the stocks that investors could look into under such circumstances is that of Northwest Biotherapeutics (OTCMKTS:NWBO). The stock has emerged as one of the stronger performers over the past year and during that period; it has clocked gains of as much as 135%. There has been no news about the company in the past few months but back in May the company made a major announcement.

Northwest is looking to develop a product named DCVax, which is meant for treating solid tumour cancers and at the time the company announced that it applied for certification of its manufacturing plant at Sawston, United Kingdom.

The application for the same was sent to the Medicines and Healthcare Products Regulatory Agency (MHRA). In addition to that, at the same time, Northwest also provided a positive update from the Phase III clinical trial of its product DCVax-L. There has been no further update in recent months but it is a stock that could be tracked closely.